Report cover image

United Kingdom Cardiovascular Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

Publisher Mordor Intelligence Inc
Published Jul 18, 2025
Length 110 Pages
SKU # MOI20477229

Description

United Kingdom Cardiovascular Devices Market Analysis

The UK cardiovascular devices market size is USD 2.55 billion in 2025 and is projected to reach USD 3.48 billion by 2030, expanding at a 6.45% CAGR during the forecast period. Robust NHS capital funding, virtual ward roll-outs and rapid uptake of AI-enabled diagnostics are sustaining momentum even as post-Brexit regulatory duplication adds cost and complexity. Demand is concentrating around minimally invasive systems that shorten hospital stays, with transcatheter valve and pulsed-field ablation platforms becoming mainstay therapies. Supply-chain pressures have encouraged domestic manufacturing initiatives, while sustainability mandates are spurring investment in recyclable single-use catheters. Competitive dynamics remain intense, with strategic acquisitions and AI-centric product launches reshaping technology leadership.

United Kingdom Cardiovascular Devices Market Trends and Insights

NHS Long-Term Plan Funding Boost for Cardiac Networks Accelerating Device Adoption

Targeted investments channelled through the GBP 25.7 billion NHS uplift for 2024-2025 are modernising cardiac networks and enabling faster technology rotation . Allocating GBP 1.5 billion to surgical hubs and GBP 70 million to advanced radiotherapy suites gives trusts the capacity to clear procedure backlogs while integrating novel devices. The NHS 10-Year Plan ties procurement to measurable outcomes, favouring vendors with strong clinical-evidence files. Integrated care systems encourage cross-trust purchasing, increasing order volumes and shortening adoption cycles by up to two years. These funding streams thus reinforce first-mover advantages for innovators with proven value propositions.

Rapid Uptake of Remote Cardiac Monitoring under NHS “Virtual Wards” Programme

NHS England aims to deliver 50,000 virtual-ward beds by 2025, fundamentally redesigning cardiac care pathways. Early pilots such as the Northern Care Alliance’s 500-bed model cut acute admissions by 30%, validating the service design at scale. NICE guidance endorsing HeartLogic and TriageHF technologies, which reduce heart-failure hospitalisations by up to 72%, further underpins rapid diffusion. Academic studies at Imperial College Healthcare show 76% fewer readmissions when tele-monitoring complements standard therapy. Savings of GBP 1,958 per patient strengthen the business case, opening new revenue channels for device makers aligned with NHS digital architecture.

High Failure-Recall Rates of Certain Stent Models Eroding Clinician Confidence

Class I recalls involving Boston Scientific’s Accolade pacemakers and Abbott’s Assurity series have shaken trust, prompting closer scrutiny of new technologies. MHRA reforms effective June 2025 demand active surveillance and faster incident reporting, raising compliance costs and delaying launches. Adverse publicity extends beyond recalled SKUs, dampening uptake across adjacent product categories. Clinicians now seek extensive post-market data before switching platforms, lengthening sales cycles and elevating barriers for SMEs.

Other drivers and restraints analyzed in the detailed report include:

  1. Growing Backlog of Elective Cardiac Procedures Driving Shift to Minimally Invasive Devices
  2. Increasing Prevalence of Atrial Fibrillation in Ageing UK Population Raising Demand for Rhythm-Management Devices
  3. NHS Workforce Shortage Constraining Equipment Replacement Cycles

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Therapeutic and surgical platforms generated 58.20% of 2024 revenues, sustained by well-resourced cardiac centres performing high-value interventions. Uptake of ultrathin drug-eluting stents and TAVR systems illustrates how procedural efficiency steers purchasing decisions. Abbott’s AVEIR leadless pacemaker, now under breakthrough-device designation, shows the innovation premium vendors can command .

Diagnostic and monitoring solutions, though smaller today, are projected to grow at a 6.98% CAGR through 2030 as prevention and remote care take centre stage. AI-enabled ECG devices that rival 12-lead hospital units underscore this momentum. Virtual-ward expansion embeds remote telemetry in standard care pathways, lifting recurring revenue from cloud analytics. Consequently, the UK cardiovascular devices market size for diagnostics is on path to outstrip therapeutics in growth pace, reshaping revenue mixes over the decade.

The UK Cardiovascular Devices Market Report is Segmented by Product Type (Diagnostic & Monitoring Devices, Therapeutic & Surgical Devices), Application (Coronary Artery Disease, Arrhythmia & Conduction Disorders, Heart Failure & Cardiomyopathy, Structural & Congenital Heart Defects, and More), End User (Hospitals & Cardiac Centres, Ambulatory Surgical Centres, and More). The Market Forecasts are Provided in Terms of Value (USD).

List of Companies Covered in this Report:

  1. Medtronic
  2. Abbott Laboratories
  3. Boston Scientific
  4. Edward Lifesciences
  5. Koninklijke Philips
  6. Siemens Healthineers
  7. Johnson & Johnson (Biosense Webster & Cordis)
  8. GE Healthcare Technologies Inc.
  9. Terumo
  10. B. Braun
  11. BIOTRONIK
  12. LivaNova
  13. MicroPort
  14. Cook Group
  15. W. L. Gore & Associates
  16. Getinge AB (Maquet)
  17. Merit Medical Systems
  18. Shockwave Medical Inc.
  19. Penumbra
  20. SynCardia Systems
  21. Nipro
  22. Corin Group PLC

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Please note: The report will take approximately 2 business days to prepare and deliver.

Table of Contents

110 Pages
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
3.1 Market Landscape
3.2 Market Overview
3.3 Market Drivers
3.3.1 NHS Long-Term Plan Funding Boost for Cardiac Networks Accelerating Device Adoption
3.3.2 Rapid Uptake of Remote Cardiac Monitoring under NHS “Virtual Wards” Programme
3.3.3 Growing Backlog of Elective Cardiac Procedures Driving Shift to Minimally Invasive Devices
3.3.4 Increasing Prevalence of Atrial Fibrillation in Ageing UK Population Raising Demand for Rhythm Management Devices
3.3.5 Government Procurement Frameworks Favouring Environmentally Sustainable Single-Use Catheters
3.3.6 Post-Brexit Regulatory Duplication Increasing Approval Costs for SMEs
3.4 Market Restraints
3.4.1 High Failure-Recall Rates of Certain Stent Models Eroding Clinician Confidence
3.4.2 NHS Workforce Shortage Constraining Equipment Replacement Cycles
3.4.3 Import-led Inflation Raising ASPs of High-tech Devices Post-Brexit
3.4.4 UKCA Certification Uncertainty Deterring SME Product Launches
3.5 Value/ Supply-Chain Analysis
3.6 Regulatory Landscape
3.7 Technological Outlook
3.8 Porter’s Five Forces
3.8.1 Threat of New Entrants
3.8.2 Bargaining Power of Suppliers
3.8.3 Bargaining Power of Buyers
3.8.4 Threat of Substitutes
3.8.5 Competitive Rivalry
4 Market Size & Growth Forecasts (Value)
4.1 By Product Type
4.1.1 Diagnostic & Monitoring Devices
4.1.1.1 ECG Systems
4.1.1.2 Remote Cardiac Monitor
4.1.1.3 Cardiac MRI
4.1.1.4 Cardiac CT
4.1.1.5 Echocardiography / Ultrasound
4.1.1.6 Fractional Flow Reserve (FFR) Systems
4.1.2 Therapeutic & Surgical Devices
4.1.2.1 Coronary Stents
4.1.2.1.1 Drug-Eluting Stents
4.1.2.1.2 Bare-Metal Stents
4.1.2.1.3 Bioresorbable Stents
4.1.2.2 Catheters
4.1.2.2.1 PTCA Balloon Catheters
4.1.2.2.2 IVUS/OCT Catheters
4.1.2.3 Cardiac Rhythm Management
4.1.2.3.1 Pacemakers
4.1.2.3.2 Implantable Cardioverter Defibrillators
4.1.2.3.3 Cardiac Resynchronization Therapy Devices
4.1.2.4 Heart Valves
4.1.2.4.1 TAVR/TAVI
4.1.2.4.2 Mechanical Valves
4.1.2.4.3 Tissue/Bioprosthetic Valves
4.1.2.5 Ventricular Assist Devices
4.1.2.6 Artificial Hearts
4.1.2.7 Grafts & Patches
4.1.2.8 Other Cardiovascular Surgical Devices
4.2 By Application
4.2.1 Coronary Artery Disease
4.2.2 Arrhythmia & Conduction Disorders
4.2.3 Heart Failure & Cardiomyopathy
4.2.4 Structural & Congenital Heart Defects
4.2.5 Peripheral Vascular Disease
4.3 By End User
4.3.1 Hospitals & Cardiac Centres
4.3.2 Ambulatory Surgical Centres
4.3.3 Cardiology/EP Clinics
4.3.4 Home-care & Remote Monitoring Programs
5 Competitive Landscape
5.1 Market Concentration
5.2 Market Share Analysis
5.3 Company Profiles {(includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)}
5.3.1 Medtronic plc
5.3.2 Abbott Laboratories
5.3.3 Boston Scientific Corporation
5.3.4 Edwards Lifesciences Corporation
5.3.5 Koninklijke Philips N.V. (Philips Healthcare)
5.3.6 Siemens Healthineers AG
5.3.7 Johnson & Johnson (Biosense Webster & Cordis)
5.3.8 GE Healthcare Technologies Inc.
5.3.9 Terumo Corporation
5.3.10 B. Braun Melsungen AG
5.3.11 Biotronik SE & Co. KG
5.3.12 LivaNova PLC
5.3.13 MicroPort Scientific Corporation
5.3.14 Cook Medical LLC
5.3.15 W. L. Gore & Associates Inc.
5.3.16 Getinge AB (Maquet)
5.3.17 Merit Medical Systems Inc.
5.3.18 Shockwave Medical Inc.
5.3.19 Penumbra Inc.
5.3.20 SynCardia Systems LLC
5.3.21 Nipro Corporation
5.3.22 Corin Group PLC
6 Market Opportunities & Future Outlook
6.1 White-Space & Unmet-Need Assessment

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us